The primary objective of the trial is to establish the effects of dietary sulfur amino acid (SAA) restriction on body weight, body composition and energy expenditure in humans.
Dietary SAA restriction is an established model for increasing lifespan and improving metabolic health in animal studies. Data from human studies are limited. In this study the investigators will perform an 8-week dietary intervention with SAA restriction to characterise the effects on several parameters related to metabolic health including body weight, body composition, energy expenditure, lipid profile and gene expression profiles in adipose tissue. The aim is to translate findings from previous animal experiments to humans
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
61
Diet with low content of methionine and cysteine
Diet with high content of methionine and cysteine
Centre for Clinical Nutrition, University of Oslo/Oslo University Hospital
Oslo, Norway
Changes in body weight
Kilograms
Time frame: At baseline, 4 and 8 weeks
Changes in resting energy expenditure
Kilocalories
Time frame: At baseline, 4 and 8 weeks
Changes in substrate oxidation
Respiratory quotient
Time frame: At baseline, 4 and 8 weeks
Changes in body composition
Fat mass (kilograms) and lean mass (kilograms)
Time frame: At baseline, 4 and 8 weeks
Changes in plasma concentrations of SAA and related intermediates and compounds
Sulfite, thiosulfate, rhodanide, sulfate, total aminothiols (homocysteine, cysteine, glutathione gamma-glutamylcysteine, cysteinylglycine, cysteamine), and fractions of total cysteine, total glutathione and total homocysteine, cystathionine, lanthionine, homolanthionine, taurine hypotaurine, sarcosine, hydrogen sulfide, S-adenosylmethionine and S-adenosylhomocysteine
Time frame: At baseline, 4 and 8 weeks
Changes in urine concentrations of SAA and related intermediates and compounds
Including sulfite, thiosulfate, rhodanide, sulfate, total aminothiols (homocysteine, cysteine, glutathione gamma-glutamylcysteine, cysteinylglycine, cysteamine)
Time frame: At baseline, 4 and 8 weeks
Changes in concentrations of plasma lipid profile
Fatty acids, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, ApoA1, ApoB
Time frame: At baseline, 4 and 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Changes in plasma makers of insulin sensitivity
Concentrations of glucose and insulin
Time frame: At baseline, 4 and 8 weeks
Changes in plasma concentrations of adipokines and appetite hormones
Leptin, adiponectin, gastrin, ghrelin, cholecystokinin (CCK), glucagon-like peptide (GLP-1), oxyntomodulin, gastric inhibitory peptide (GIP), peptide YY (PYY), and pancreatic peptide (PP).
Time frame: At baseline, 4 and 8 weeks
Changes in gene expression
mRNA of proteins involved in SAA metabolism, lipid and energy metabolism in leucocytes and subcutaneous white adipose tissue samples
Time frame: At baseline, 4 and 8 weeks
Vitamin status
Plasma concentrations of folate, B12 and methylmalonic acid (MMA)
Time frame: At baseline, 4 and 8 weeks
Changes in biomarkers related to obesity and energy metabolism
Untargeted analyses of plasma, serum and tissue concentrations
Time frame: At baseline, 4 and 8 weeks
Changes in fibroblast growth factor 21 (FGF21)
Serum concentrations
Time frame: At baseline, 4 and 8 weeks
Nitrogen balance
24 h-urine urea nitrogen
Time frame: At baseline, 4 and 8 weeks
Changes in gut microbiota
Sequencing of fecal samples
Time frame: At baseline, 4 and 8 weeks
Changes in short chain fatty acids
Fecal concentrations
Time frame: At baseline, 4 and 8 weeks